Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

Mass spectrometry (MS) is a promising tool for monitoring monoclonal protein in plasma cell dyscrasias. We included 480 transplant-eligible newly-diagnosed multiple myeloma (MM) patients from the GMMG-MM5 trial (EudraCT No. 2010-019173-16) and performed a retrospective MS analysis at baseline (480 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Mai, Elias K., Huhn, Stefanie, Miah, Kaya, Poos, Alexandra M., Scheid, Christof, Weisel, Katja C., Bertsch, Uta, Munder, Markus, Berlanga, Oscar, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Blau, Igor W., Hänel, Mathias, Salwender, Hans J., Benner, Axel, Raab, Marc S., Goldschmidt, Hartmut, Weinhold, Niels
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812999/
https://www.ncbi.nlm.nih.gov/pubmed/36599831
http://dx.doi.org/10.1038/s41408-022-00772-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812999/
https://www.ncbi.nlm.nih.gov/pubmed/36599831
http://dx.doi.org/10.1038/s41408-022-00772-9

Ejemplares similares